'מערכת אימד'Peyrin‑Biroulet et.al.; BMC Gastroenterology 2022 Jun 8;22(1):291
Abstract
Background and aims: There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1. PMID: 35676620; PMCID: PMC9178865.